MS Clinical Trials in Tennessee
27 active trials · 12 recruiting
27 active multiple sclerosis clinical trials have at least one study site in Tennessee, 12 of them currently recruiting participants. Trials are listed from ClinicalTrials.gov and cover disease-modifying therapies, symptom treatments, rehabilitation and imaging studies.
Eligibility, contact details and the exact site address are on each trial's ClinicalTrials.gov record, linked from every trial page. MS Buddy also lists 8 MS treatment centers in Tennessee; many trial sites are run from those centers, and your neurologist is the best first person to ask about joining a study.
Active MS trials with sites in Tennessee
RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Sponsor: TG Therapeutics, Inc.
Ublituximab · Placebo
25 states800 participantsDetails ›
RecruitingPhase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Sponsor: Novartis Pharmaceuticals
Remibrutinib oral treatment · Ocrelizumab
18 states360 participantsDetails ›
RecruitingPhase 2
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Sponsor: Hoffmann-La Roche
Ocrelizumab Test Formulation · Ocrelizumab Reference Formulation
8 states182 participantsDetails ›
RecruitingPhase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
Sponsor: Amgen
Ocrelizumab (US) · Ocrelizumab (EU)
17 states444 participantsDetails ›
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Sponsor: Novartis Pharmaceuticals
Remibrutinib (blinded) · Placebo
10 states1275 participantsDetails ›
RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Sponsor: Celgene
BMS-986368 · Placebo
11 states200 participantsDetails ›
RecruitingPhase 3
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Sponsor: Sanofi
Frexalimab · Frexalimab
6 states160 participantsDetails ›
RecruitingPhase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Sponsor: Sanofi
Frexalimab · Teriflunomide
35 states1600 participantsDetails ›
Recruiting
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Sponsor: TG Therapeutics, Inc.
No Intervention
29 states500 participantsDetails ›
Recruiting
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
Sponsor: TG Therapeutics, Inc.
No intervention
4 states16 participantsDetails ›
RecruitingPhase 3
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Sponsor: Sanofi
Frexalimab · Placebo
38 states900 participantsDetails ›
RecruitingNA
Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis
Sponsor: Accelerated Cure Project for Multiple Sclerosis
Online Program for Fatigue
6 states2000 participantsDetails ›
Closed to new patientsPhase 3
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
Sponsor: Hoffmann-La Roche
Ocrelizumab · Ocrelizumab
16 states769 participantsDetails ›
Closed to new patientsPhase 3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Sponsor: Novartis Pharmaceuticals
Remibrutinib · Teriflunomide
23 states1011 participantsDetails ›
Closed to new patientsPhase 4
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Sponsor: Novartis Pharmaceuticals
Ofatumumab · Disease modifying treatment (DMT)
19 states136 participantsDetails ›
Closed to new patientsPhase 2
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
Sponsor: Eli Lilly and Company
LY3541860 · Placebo
5 states63 participantsDetails ›
Closed to new patientsPhase 3
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
Sponsor: Hoffmann-La Roche
Fenebrutinib · Ocrelizumab
24 states985 participantsDetails ›
Closed to new patientsPhase 3
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
Sponsor: Novartis Pharmaceuticals
Ofatumumab approved dose · Ofatumumab new dose
24 states196 participantsDetails ›
Closed to new patientsPhase 3
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Sponsor: Hoffmann-La Roche
Fenebrutinib · Teriflunomide
13 states751 participantsDetails ›
Closed to new patientsPhase 3
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Sponsor: Novartis Pharmaceuticals
Ofatumumab · Tetanus toxoid (TT) containing vaccin…
32 states1882 participantsDetails ›
Closed to new patientsPhase 3
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
Sponsor: TG Therapeutics, Inc.
Ublituximab
14 states1100 participantsDetails ›
Closed to new patientsPhase 3
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Sponsor: Hoffmann-La Roche
Fenebrutinib · Teriflunomide
23 states746 participantsDetails ›
Closed to new patientsPhase 3
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
Sponsor: Hoffmann-La Roche
Ocrelizumab · Ocrelizumab
20 states864 participantsDetails ›
Closed to new patientsPhase 3
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Sponsor: Sanofi
Tolebrutinib · Placebo
27 states2500 participantsDetails ›
Closed to new patientsPhase 3
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
Sponsor: Hoffmann-La Roche
Ocrelizumab
26 states1300 participantsDetails ›
Closed to new patientsPhase 3
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
Sponsor: Hoffmann-La Roche
Ocrelizumab
13 states927 participantsDetails ›
Closed to new patientsNA
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
Sponsor: Johns Hopkins University
Natalizumab/natalizumab-sztn, Alemtuz… · Glatiramer acetate, Interferons (intr…
28 states900 participantsDetails ›
MS trials in other states
The app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.